Your browser doesn't support javascript.
loading
Associations of functional, psychosocial, medical, and socio-demographic factors with cognitive screening in chemotherapy naïve patients with breast cancer.
Nakamura, Zev M; Deal, Allison M; Nyrop, Kirsten A; Choi, Seul Ki; Wood, William A; Muss, Hyman B.
Afiliação
  • Nakamura ZM; Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Deal AM; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Nyrop KA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Choi SK; Department of Medicine, Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Wood WA; Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Muss HB; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Psychooncology ; 28(1): 167-173, 2019 01.
Article em En | MEDLINE | ID: mdl-30353629
ABSTRACT

OBJECTIVE:

To describe associations of functional, psychosocial, medical, and socio-demographic factors with performance on a cognitive screening test in chemotherapy naïve patients with breast cancer.

METHODS:

Women with breast cancer were recruited between 2009 and 2018. The Blessed Orientation Memory Concentration Test (BOMC) was administered prior to chemotherapy. Associations between baseline BOMC and functional (Karnofsky Self-Reported Performance Rating Scale (KPS), Time Up and Go Test (TUG), Medical Outcomes Study (MOS) Physical Function, Instrumental Activities of Daily Living (IADL)), psychosocial (Mental Health Inventory-13, MOS Social Activity Limitation and Social Support Survey), medical, and socio-demographic variables were assessed using linear regression analysis.

RESULTS:

In a sample of 331 women with breast cancer, the mean age was 65.2 years and 68.6% were 65 and older. Mean BOMC score was 3.60 on a scale from 0 (best) to 28 (worst). After controlling for demographic factors, worse BOMC screening test results were associated with KPS < 80 (P = 0.01), IADL<14 (P = 0.02), TUG ≥14 seconds (P = 0.001), worse MOS Physical Function (P = 0.0006), depressive symptoms (P = 0.04), and social activity limitations (P = 0.01).

CONCLUSION:

In a sample of women with breast cancer, pre-treatment cognitive screening scores did not reveal profound cognitive impairment. BOMC screening scores were associated with multiple measures of physical function, but further research is needed to determine a clinically meaningful cut point in the BOMC for screening of cancer-related cognitive impairment.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Disfunção Cognitiva Tipo de estudo: Diagnostic_studies / Etiology_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies / Screening_studies Limite: Aged / Aged80 / Female / Humans / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Disfunção Cognitiva Tipo de estudo: Diagnostic_studies / Etiology_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies / Screening_studies Limite: Aged / Aged80 / Female / Humans / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article